Exelixis Total Current Assets Over Time
| EXEL Stock | USD 36.38 0.77 2.16% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Exelixis Performance and Exelixis Correlation. Exelixis |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 121.699 | Earnings Share 1.55 | Revenue Per Share 7.032 | Quarterly Revenue Growth 0.143 | Return On Assets 0.1281 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Assets Analysis
Compare Exelixis and related stocks such as TG Therapeutics, Viking Therapeutics, and Madrigal Pharmaceuticals Total Current Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TGTX | 2.3 M | 9.8 M | 18.5 M | 42.3 M | 85.2 M | 86.9 M | 50.9 M | 93.3 M | 79 M | 149.2 M | 611.7 M | 331 M | 168.3 M | 317.9 M | 333.8 M |
| VKTX | 179.6 K | 179.6 K | 179.6 K | 179.6 K | 773.7 K | 15.2 M | 14 M | 21.9 M | 302.1 M | 283.5 M | 256.1 M | 210.5 M | 167 M | 367.2 M | 385.6 M |
| MDGL | 77.1 M | 40.3 M | 101.4 M | 92.2 M | 99.3 M | 67.8 M | 41.2 M | 192 M | 485.2 M | 440.2 M | 285.2 M | 271.7 M | 361.4 M | 637.3 M | 669.1 M |
| BTAI | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 2 K | 890 K | 43.2 M | 34.1 M | 217.1 M | 233 M | 202.9 M | 72.1 M | 98.2 M |
| BMRN | 12.8 M | 469.8 M | 743.5 M | 1.1 B | 1.4 B | 1.1 B | 1.4 B | 2.2 B | 2.1 B | 1.9 B | 2.3 B | 2.3 B | 2.8 B | 3 B | 3.1 B |
| ALNY | 15.5 M | 266.4 M | 229 M | 358.6 M | 1 B | 1.4 B | 989.2 M | 1.8 B | 1.2 B | 1.7 B | 2.2 B | 2.9 B | 2.7 B | 3 B | 3.1 B |
| HALO | 26.1 K | 64 M | 131 M | 95.2 M | 161.3 M | 171.8 M | 256.5 M | 510.4 M | 427.8 M | 543.4 M | 554.8 M | 926.3 M | 739 M | 746.4 M | 783.7 M |
| XFOR | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 5.7 M | 80.8 M | 35.1 M | 129.3 M | 83.3 M | 87.9 M | 128.7 M | 122.1 M | 83.3 M |
| PDSB | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 15.4 M | 131.3 M | 107.4 M | 89.1 M | 35.7 M | 14.5 M | 30.3 M | 66.8 M | 76.5 M | 59.1 M | 63.4 M |
| PTCT | 33.1 M | 33.1 M | 4.6 M | 145 M | 323.6 M | 355.9 M | 261.3 M | 249.1 M | 320.9 M | 779.3 M | 1.2 B | 773.4 M | 693.8 M | 1.2 B | 1.3 B |
| KRYS | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 49.9 M | 112.7 M | 195.9 M | 275.1 M | 442.3 M | 383.8 M | 587.9 M | 617.3 M |
| KOD | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 1.6 M | 90.4 M | 339.2 M | 972 M | 734.8 M | 486 M | 289.3 M | 402 M |
| SRPT | 900 K | 45.2 M | 193.9 M | 270.8 M | 247.8 M | 224.5 M | 373.5 M | 1.2 B | 1.4 B | 1.5 B | 2.5 B | 2.6 B | 2.6 B | 2.6 B | 2.7 B |
Exelixis and related stocks such as TG Therapeutics, Viking Therapeutics, and Madrigal Pharmaceuticals Total Current Assets description
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.My Equities
My Current Equities and Potential Positions
| Exelixis | EXEL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 36.38
Check out Exelixis Performance and Exelixis Correlation. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Exelixis technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.